Abstracts tagged "interstitial lung disease"

Abstract Number: 852 • 2016 ACR/ARHP Annual Meeting
Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Veronica Codullo¹, Emanuela Cova², Simona Inghilleri², Miriam Colombo³, Davide Prosperi³, Federica Meloni⁴ and Carlomaurizio Montecucco⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ²Clinica di Malattie dell’Apparato Respiratorio, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy, Pavia, Italy, ³Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Milan, Italy, ⁴Dipartimento di Medicina Interna, Unità di Pneumologia e UOC di Reumatologia, Università di Pavia, Pavia, Italy, ⁵Rheumatology Unit of the University Hospital of Pavia, Pavia, Italy
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune fibrotic disorder characterised by collagen and extracellular matrix deposition in the skin and internal organs, such as the…
Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Caitlyn Fisher^1,2, Rajaie Namas³, Amber Young², Holly Wilhalme⁴ and Dinesh Khanna⁵, ¹Cognitive Science / Creative Writing, Beloit College, Beloit, WI, ²Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Dinesh Khanna², Chi-hong Tseng³, Robert Elashoff⁴, Bingling Wang⁵, Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Arthur Theodore⁶ and Donald P. Tashkin⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁵Biostatistics, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine, Boston University, Boston, MA, ⁷David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Jeffrey J. Swigris⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Katherine Larson¹, Faizah Siddique² and Samya Mohammad¹, ¹Virginia Commonwealth University, Richmond, VA, ²Department of Veterans Affairs, Richmond, VA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
Abstract Number: 1559 • 2016 ACR/ARHP Annual Meeting
Shared Genetic Predisposition in Rheumatoid Arthritis–Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: A Genetic Association Study
Pierre-Antoine Juge¹, Raphaël Borie², Caroline Kannengiesser³, Steven Gazal³, Patrick Revy⁴, Lidwine Wemeau-Stervinou⁵, Marie-Pierre Debray⁶, Sébastien Ottaviani⁷, Sylvain Adam-Marchand⁸, Nadia Nathan⁹, Gabriel Thabut¹⁰, Christophe Richez¹¹, Hilario Nunes¹², Isabelle Callebaut¹³, Aurélien Justet², Nicolas Leulliot¹⁴, Amélie Bonnefond¹⁵, David Salgado¹⁶, Pascal Richette¹⁷, Jean-Pierre Desvignes¹⁶, Huguette Lioté¹⁸, Philippe Froguel¹⁵, Yannick Allanore¹⁹, Olivier Sand¹⁵, Claire Dromer²⁰, René-Marc Flipo²¹, Annick Clément⁹, Christophe Béroud²², Jean Sibilia²³, Baptiste Coustet^1,24, Vincent Cottin²⁵, Marie-Christophe Boissier²⁶, Benoit Wallaert²⁷, Thierry Schaeverbeke²⁸, Florence Dasto le Moal²⁹, Aline Frazier¹⁷, Christelle Ménard³⁰, Martin Soubrier³¹, Nathalie Saidenberg²⁹, Dominique Valeyre³², Serge Amselem⁹, Catherine Boileau³, Bruno Crestani² and Philippe Dieudé¹, ¹Rhumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ²Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, ³Génétique, Hôpital Bichat - Claude Bernard, Paris, France, ⁴Laboratory of Genome Dynamics in the Immune System, Institut Imagine, Paris, France, ⁵Pneumologie, CHRU de Lille, Lille, France, ⁶Université Paris-Diderot, Paris, France, ⁷Rheumatologie, Hôpital Bichat - Claude Bernard, Paris, France, ⁸Pneumology, Centre Hospitalier Universitaire de Tours, Tours, France, ⁹Pneumologie pédiatrique, Hôpital Trousseau, Paris, France, ¹⁰Pneumologie B, Hôpital Bichat - Claude Bernard, Paris, France, ¹¹Rhumatologie, Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ¹²Pneumologie B, Hôpital Avicenne, Paris, France, ¹³CNRS UMR_7590, Paris, France, ¹⁴Laboratoire de cristallographie et RMN biologiques, UMR CNRS 8015, Paris, France, ¹⁵CNRS UMR_8199, Lille, France, ¹⁶UMR_S 910, Marseille, France, ¹⁷Rhumatologie, Hôpital Lariboisière, Paris, France, ¹⁸Pneumologie A, Hôpital Tenon, Paris, France, ¹⁹Rhumatologie A, Hôpital Cochin, Paris, France, ²⁰Imagerie Thoracique et Cardiovasculaire, CHU Bordeaux, Bordeaux, France, ²¹Rhumatologie, CHU Lille, Lille, France, ²²INSERM UMR_S 910, Marseille, France, ²³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²⁴Rheumatology, Université Paris Descartes, Hopital Cochin, Paris, France, ²⁵Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ²⁶Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²⁷Pneumology, CHRU, Lille CEDEX, France, ²⁸Rheumatology, CHU Bordeaux, Bordeaux, France, ²⁹Rhumatologie, Hôpital Avicenne, Paris, France, ³⁰Pneumologie Pédiatrique, Hôpital Trousseau, Paris, France, ³¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ³²Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality for rheumatoid arthritis (RA) patients. Despite its high prevalence and mortality, little…
Abstract Number: 30 • 2016 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis
Dam Kim¹, Soo-Kyung Cho², Chan-Bum Choi³, Jung-Yoon Choe⁴, Won Tae Chung⁵, Seung-Jae Hong⁶, Young Ok Jung⁷, Tae-Hwan Kim⁸, Tae-Jong Kim⁹, Hye-Soon Lee¹⁰, Joo Hyun Lee¹¹, Jisoo Lee¹², Shin-Seok Lee¹³, Dae-Hyun Yoo¹⁴, Bo Young Yoon¹⁵, Jin Woo Song¹⁶, Sang-Cheol Bae¹⁷ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, ⁵Rheumatology, Dong-A University Hospital, Busan, South Korea, ⁶Dept. of Rheumatology, #1 Hoeg, KyungHee University Medical Center, SEOUL, South Korea, ⁷Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ⁸Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹²Int Medicine, Ewha Woman's Univ Schl of Med, Seoul, Korea, Republic of, ¹³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of, ¹⁴Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁵Rheumatology/Internal medicine, Inje Iniversity Ilsan Paik Hospital, Goyang, Korea, The Republic of, ¹⁶Department of pulmonary and critical care of medicine, Asan medical center, University of Ulsan, College of Medicine, Seoul, Korea, The Republic of, ¹⁷Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, The Republic of
Background/Purpose: Some studies have supported ethnicity-related differences in the prevalence of ILD and ILD in RA; however, these results have not yet been conclusive.…
Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Jennifer Medlin¹, Karen Hansen², Sara McCoy³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…
Abstract Number: 274 • 2016 ACR/ARHP Annual Meeting
Splicing Factor Proline/Glutamine-Rich Is a Novel Autoantigen of Dermatomyositis and Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody.
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami¹, Yoshitaka Imura¹, Satoshi Serada², Minoru Fujimoto³, Hajime Yoshifuji¹, Koichiro Ohmura⁴, Tetsuji Naka⁵ and Tsuneyo Mimori⁴, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Laboratory for Immune Signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ³Laboratry of immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan, ⁴Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Laboratory for immune signal, National Institute of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan
Background/Purpose: Anti- melanoma differentiation-associated gene 5 (MDA5) antibody positive dermatomyositis (DM) and clinically amyopathic DM (CADM) often develop rapidly progressive interstitial lung disesase (RP-ILD),…
Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Amber Young¹, Caitlyn Fisher¹, Rajaie Namas², Holly Wilhalme³ and Dinesh Khanna⁴, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 1884 • 2016 ACR/ARHP Annual Meeting
Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann², Carrie Richardson^3,4, Julia (Jungwha) Lee⁵, David Aaby⁶, Rishi Agrawal⁷, Jane Dematte⁸, Rowland W. Chang⁹ and Monique Hinchcliff¹⁰, ¹Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ⁴Department of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Preventive Medicine/Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Pulmonology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD.…
Abstract Number: 1076 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Michael Roth², Robert Elashoff³, Philip J. Clements¹, Daniel E. Furst², Dinesh Khanna⁴, Jonathan Goldin⁵, Donald Tashkin¹ and Scleroderma Lung Study II Group, ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine, University of Michigan, Ann Arbor, MI, ⁵David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although cyclophosphamide (CYC) demonstrated beneficial treatment effects at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].